New immune therapy aims to knock out lingering hepatitis b
Disease control
Ongoing
This study is testing whether a new two-part immunotherapy called VTP-300, given with a low dose of an existing drug (nivolumab), can help the body's immune system better control chronic Hepatitis B. It involves 120 adults whose virus is already suppressed by daily pills. The mai…
Phase: PHASE2 • Sponsor: Barinthus Biotherapeutics • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC